Is CRMD Stock a Buy Now After Strong Growth and New Risks?
CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes and execution risks could shape the stock's next phase.
CRMD - CorMedix Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$13.33
DETAILS
HIGH:
$14.00
LOW:
$13.00
MEDIAN:
$13.00
CONSENSUS:
$13.33
UPSIDE:
58.69%
Stock News
CRMD's Growth Story Expands Beyond DefenCath Into New Trends
CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reimbursement changes test long-term earnings durability.
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential despite reimbursement headwinds.
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the Northern District of Illinois that the patents covering its product MINOCIN® for Injection are valid and infringed by the product developed by Nexus Pharmaceuticals, Inc.
CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long Run
CorMedix is rated a 'Strong Buy' below ~$8.35, with ~114% upside to a $17.5 fair value based on DCF modeling. CRMD faces a 2027 revenue trough post-TDAPA, but I expect growth to reignite from 2027 to 2028, driven by DefenCath adoption and pipeline progress. Key mid-to-long-term catalysts include potential DaVita onboarding, federal market expansion, and pipeline assets like DefenCath TPN and REZZAYO.
CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms
CorMedix NASDAQ: CRMD CEO Joe said the company is preparing for several potential commercial and regulatory catalysts across its infectious disease and dialysis-related portfolio, including a possible expansion of REZZAYO into fungal infection prophylaxis and continued work to sustain DefenCath utilization through changes in federal reimbursement.
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
CorMedix beats Q1 estimates as DefenCath demand surges and raises 2026 guidance on stronger execution and growing profitability.
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that management will be participating in fireside chats and investor meetings at both the RBC Capital Markets Global Healthcare Conference being held in New York on May 19 – 20, 2026 and the Jefferies Global Healthcare Conference being held in New York on June 2 – 4, 2026. Details for each fireside chat is as follows:
CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised
CorMedix Therapeutics Inc. (NASDAQ:CRMD) raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting strong first-quarter results driven by higher utilization of DefenCath and contributions from the acquired Melinta portfolio.
CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
CorMedix Q1 Earnings Call Highlights
CorMedix NASDAQ: CRMD reported sharply higher first-quarter 2026 revenue and profit, driven by continued adoption of DefenCath and the addition of products from its Melinta acquisition, while management raised its full-year financial outlook and outlined key pipeline developments.
CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates
CorMedix (CRMD) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.3 per share a year ago.
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
‒ Q1 2026 Net Revenue of $127.4 million ‒ ‒ Q1 2026 Net Income of $38.6 million ; Adjusted EBITDA of $70.0 million ‒ ‒ Company raises FY 2026 Revenue and Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J.
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the first quarter ended March 31, 2026, before the market opens on Thursday, May 14, 2026, and will host a corporate update conference call at 8:30am Eastern Time.
CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study
CorMedix Inc. (NASDAQ:CRMD) shares are up on Monday following the announcement of positive topline results from the Phase 3 ReSPECT trial assessing REZZAYO (rezafungin) for the prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic blood and marrow transplant.
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 –
CorMedix: A Shrinking Core And No Proven Second Engine
CorMedix is entering a post-TDAPA reset, with DefenCath revenue expected to decline materially and no proven second growth engine in place. FY26 guidance of ~$310M (midpoint) masks underlying deceleration, as DefenCath declines from $258.8M in FY25 to $150M–$170M in FY26, with the year-end run rate likely materially weaker heading into FY27. Rezzayo and DefenCath TPN offer long-term optionality but lack current financial contribution, while Melinta provides stability rather than growth.
CorMedix to Participate in Needham Virtual Healthcare Conference
PARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be participating in a fireside chat and investor meetings at the upcoming 25th Annual Needham Virtual Healthcare Conference taking place April 13 – 16, 2026.
CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript
CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript
Price Targets
CorMedix price target raised to $14 from $13 at RBC Capital
$14.00
(was $7.82)
Leonid Timashev
·
RBC Capital
CorMedix (CRMD) PT Lowered to $13 at Leerink Partners
$13.00
(was $6.46)
Roanna Ruiz
·
Leerink Partners
CorMedix price target lowered to $13 from $18 at H.C. Wainwright
$13.00
(was $7.44)
H.C. Wainwright
CorMedix price target lowered to $13 from $22 at RBC Capital
$13.00
(was $6.88)
RBC Capital
CorMedix price target lowered to $16 from $20 at Truist
$16.00
(was $7.44)
Truist Financial
CorMedix price target raised to $22 from $21 at RBC Capital
$22.00
(was $12.16)
Gregory Renza
·
RBC Capital
CorMedix price target lowered to $17 from $20 at H.C. Wainwright
$17.00
(was $10.33)
Brandon Folkes
·
H.C. Wainwright
CorMedix (CRMD) PT Lowered to $9 at RBC Capital
$9.00
(was $3.90)
Gregory Renza
·
RBC Capital